ERNA — Eterna Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $6.93m
- $13.79m
- $0.07m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -2.05 | -4.42 | -122 | -24.6 | -21.7 |
Depreciation | |||||
Non-Cash Items | 2.29 | -0.134 | 101 | -0.268 | 3.29 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.374 | -1.08 | -2.35 | 3.71 | -2.12 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 2.74 | -3.89 | -23.5 | -21 | -20.4 |
Capital Expenditures | -1.09 | -0.266 | -0.154 | -0.297 | -0.019 |
Purchase of Fixed Assets | |||||
Software Development Costs | |||||
Other Investing Cash Flow Items | 0.029 | 1.23 | -22.6 | 0.25 | 0 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Cash from Investing Activities | -1.06 | 0.96 | -22.7 | -0.047 | -0.019 |
Financing Cash Flow Items | -0.037 | -0.049 | — | -0.116 | -0.251 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -1.1 | 0.291 | 61.6 | 19.6 | 16.6 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.623 | -2.63 | 15.4 | -1.44 | -3.87 |